Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Parkinson Disease 3”

195 trials

Showing 20 of 195 results

Early research (Phase 1)Study completedNCT05635461
What this trial is testing

Relative Bioavailability and Food Effect Study of CVN424

Who this might be right for
Parkinson's Disease
Cerevance Beta, Inc. 32
Large-scale testing (Phase 3)Study completedNCT04246177
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 479
Large-scale testing (Phase 3)Study completedNCT04934722
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 186
Not applicableEnded earlyNCT02622737
What this trial is testing

Study of the Effects of Three Exercise Programs in Parkinson's Disease

Who this might be right for
Parkinson Disease
Federal University of Bahia 79
Large-scale testing (Phase 3)Study completedNCT00466167
What this trial is testing

Pivotal Study in Advanced Parkinsons Disease Patients

Who this might be right for
Parkinson Disease
Boehringer Ingelheim 517
Testing effectiveness (Phase 2)Study completedNCT02834507
What this trial is testing

Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients

Who this might be right for
Parkinson's Disease (PD)
Bial - Portela C S.A. 19
Large-scale testing (Phase 3)Study completedNCT00243971
What this trial is testing

A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease

Who this might be right for
Parkinson's Disease
UCB Pharma
Not applicableStudy completedNCT03972241
What this trial is testing

Strategy for Daily Activity Improvement in Patients With Parkinson's Disease

Who this might be right for
Parkinson Disease
Kwan-Hwa Lin 60
Large-scale testing (Phase 3)Study completedNCT03976323
What this trial is testing

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Who this might be right for
Carcinoma, Nonsquamous Non-small-cell Lung
Merck Sharp & Dohme LLC 1,003
Large-scale testing (Phase 3)Ended earlyNCT04095793
What this trial is testing

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Who this might be right for
Symptomatic Neurogenic Orthostatic Hypotension
Theravance Biopharma 110
Large-scale testing (Phase 3)Study completedNCT02358031
What this trial is testing

Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

Who this might be right for
Recurrent Head and Neck CancerMetastatic Head and Neck Cancer
Merck Sharp & Dohme LLC 882
Testing effectiveness (Phase 2)Ended earlyNCT00809302
What this trial is testing

Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease

Who this might be right for
Early Parkinson Disease
Neurogen Corporation 9
Large-scale testing (Phase 3)Active Not RecruitingNCT05239728
What this trial is testing

Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 1,800
Large-scale testing (Phase 3)Study completedNCT03635567
What this trial is testing

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Who this might be right for
Cervical Cancer
Merck Sharp & Dohme LLC 617
Large-scale testing (Phase 3)Study completedNCT00957203
What this trial is testing

Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients

Who this might be right for
Parkinson's Disease
Kyowa Kirin Co., Ltd. 308
Large-scale testing (Phase 3)Study completedNCT03976375
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Who this might be right for
Metastatic Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC 422
Large-scale testing (Phase 3)Study completedNCT03898180
What this trial is testing

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Who this might be right for
Urothelial Carcinoma
Merck Sharp & Dohme LLC 505
Testing effectiveness (Phase 2)Study completedNCT04165096
What this trial is testing

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 128
Large-scale testing (Phase 3)Study completedNCT02274766
What this trial is testing

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia

Who this might be right for
DyskinesiaLevodopa-Induced Dyskinesia (LID)Parkinson's Disease (PD)
Adamas Pharmaceuticals, Inc. 77
Large-scale testing (Phase 3)Study completedNCT03834519
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

Who this might be right for
Prostatic Neoplasms
Merck Sharp & Dohme LLC 793
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation